---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290881025.md"
description: "Taysha Gene Therapies Announces Multiple Presentations Highlighting TSHA-102 Program In Clinical Evaluation For Rett Syndrome At 2026 IRSF Rett Syndrome Scientific Meeting"
datetime: "2026-06-25T20:02:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290881025.md)
  - [en](https://longbridge.com/en/news/290881025.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290881025.md)
---

# 

Taysha Gene Therapies Announces Multiple Presentations Highlighting TSHA-102 Program In Clinical Evaluation For Rett Syndrome At 2026 IRSF Rett Syndrome Scientific Meeting

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

- [Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome](https://longbridge.com/en/news/293788160.md)
- [Taysha Gene Therapies President, Head of R&D Sukumar Nagendran disposes of 200,000 common shares for $1.25 million](https://longbridge.com/en/news/292362092.md)
- [Taysha Gene Therapies posts REVEAL Part A Phase 1/2 TSHA-102 Rett syndrome trial presentation](https://longbridge.com/en/news/291157030.md)
- [TSHA: TSHA-102 showed durable, accumulating functional gains and strong safety in Rett syndrome trials](https://longbridge.com/en/news/290435744.md)
- [Taysha Gene Therapies to present REVEAL Phase 1/2 data for Rett gene therapy TSHA-102 at 2026 IRSF meeting](https://longbridge.com/en/news/290873833.md)